Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up.
Charles G. Drake
Consultant or Advisory Role - Bristol-Myers Squibb
David F. McDermott
Consultant or Advisory Role - Bristol-Myers Squibb
Mario Sznol
Consultant or Advisory Role - Bristol-Myers Squibb
Toni K. Choueiri
Consultant or Advisory Role - AVEO; Bayer/Onyx; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Pfizer
Harriet M. Kluger
No relevant relationships to disclose
John D. Powderly
Employment or Leadership Position - BioCytics
Consultant or Advisory Role - Amplimmune; Bristol-Myers Squibb; Roche/Genentech
Stock Ownership - BioCytics
Honoraria - Bristol-Myers Squibb; Dendreon; Genentech
Research Funding - Amgen; Amplimmune; Bristol-Myers Squibb; Celldex; Genentech; ImClone Systems; Lilly; Millennium; Progenics; Regeneron
David C. Smith
Research Funding - Bristol-Myers Squibb
Vindira Sankar
Employment or Leadership Position - Bristol-Myers Squibb
Andres A. Gutierrez
Employment or Leadership Position - Bristol-Myers Squibb
Jon M. Wigginton
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Georgia Kollia
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Ashok Kumar Gupta
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Michael B. Atkins
Consultant or Advisory Role - Bristol-Myers Squibb